Recently, the final review defense for the 2025 Roche University Research Fund, organized by the Chinese Society of Biochemistry and Molecular Biology (CSBMB), was successfully concluded. The 2025 edition received 215 applications. After multiple rounds of expert review, one first prize, six second prizes, and twelve third prizes were ultimately awarded. Wang Yiru, a 2024 doctoral student from the School of Life Science and Technology (SLST) / Shanghai Institute for Advanced Immunochemical Studies (SIAIS), won the second prize. Liu Lu, a 2022 doctoral student jointly trained by SLST/SIAIS and the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences (CAS), received a Merit Award.
At the final review defense, Wang Yiru, whose research focuses on viral genome replication, transcriptional regulation mechanisms, and the development of antiviral drugs, presented her latest findings on the molecular mechanism by which non-nucleoside inhibitors suppress the activity of the RNA polymerase complex in measles virus and Nipah virus. Her solid research skills and clear presentation were highly recognized by the experts. After several rounds of strict evaluation, she stood out from over two hundred young scholars from numerous universities across the country to win the second prize.
Concurrently, Liu Lu, focusing on broad-spectrum antiviral drug research, was awarded a Merit Award for her solid work and forward-looking perspective in this fund application.
The Roche University Research Fund is a program launched in 2018 through a collaboration between Roche Diagnostics (Shanghai) Ltd. and the Chinese Society of Biochemistry and Molecular Biology (CSBMB), targeting students enrolled in universities. Its primary goals are to cultivate outstanding talent in the medical field and support the sustainable development of medical education and healthcare in China.
* This article was primarily generated by DeepSeek.